Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar in Advanced Renal Cell Carcinoma.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms POWER-NEXT
- Sponsors Bayer
- 29 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 28 Jul 2014 Planned initiation date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 10 Mar 2014 Planned initiation date changed from 1 Sep 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.